GNPX
Genprex, Inc. [GNPX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
GNPX Stock Summary
Top 10 Correlated ETFs
GNPX
Top 10 Correlated Stocks
GNPX
In the News
GNPX Financial details
Company Rating
-
Market Cap
5.12M
Income
-30.79M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
26
Optionable
No
Shortable
Yes
Earnings
22 May 2024
P/E
-0.43
Forward P/E
-
PEG
0.62
P/S
-
P/B
1.09
P/C
-
P/FCF
-0.57
Quick Ratio
2.7
Current Ratio
2.96
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-22.88
EPS next Y
-
EPS next Q
-
EPS this Y
-8.22%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-25.56%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-188%
ROE
-192%
ROC
-2.59%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.5-46.0
52W High
-99.49%
52W Low
-88.29%
RSI
28
Rel Volume
12.68
Avg Volume
88.29K
Volume
1.12M
Perf Week
-39.32%
Perf Month
-40.76%
Perf Quarter
-31.29%
Perf Half Y
-36.85%
-
-
-
-
Beta
-0.633
-
-
Volatility
0.05%, 0.04%
Prev Close
-4.48%
Price
0.2343
Change
-11.08%
Company Profile
- Volume Average 88.29K
- Market Capitalization 5.12M
- Employee 26
- CEO Mr. John Rodney Varner
- Headquarters Austin,TX,US
- IPO Date 2018-03-29
-
Website
https://www.genprex.com 
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
